News
Aurinia Appoints Max Colao as Chief Commercial Officer and Expands U.S. Commercial Leadership Team
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today
IMV Inc. Announces Breakthrough Data from DeCidE1, its Ongoing Phase 2 Study of DPX-Survivac in Patients with Advanced Recurrent Ovarian Cancer
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today reported updated results from DeCidE1, an ongoing Phase 2 study of
Clovis Oncology Announces 2019 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter and year ended December 31, 2019, and provided an update on Clovis’ clinical development programs and regulatory and
Aurinia Pharmaceuticals to Present at the 9th Annual SVB Leerink Global Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “Company”) today announced that Mr. Peter Greenleaf, President and Chief Executive Officer, will present a corporate overview at the 9th
NBC feiert Buyout-Jubiläum mit weiteren Kursgewinnen von bis zu +325%
Vor einem Jahr feierte der No Brainer Club seinen ersten Buyout und damit +303% Kursgewinn über Nacht! Weitere +325% wurden passend zum Jubiläum nun an anderer Stelle eingefahren.
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2019. Unless otherwise stated, all comparisons
First Patient Dosed With Transgene’s Oncolytic Virus TG6002, Administered by Intrahepatic Artery Infusion in Colorectal Cancer With Liver Metastases
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces that the first
IMV to Host Conference Call & Webcast to Report Updated Results from DeCidE1, its Ongoing Phase 2 Study of DPX-Survivac in Patients with Advanced Recurrent Ovarian Cancer
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that company management will host a conference call &
Cellectis and Servier Expand Collaboration on UCART19 Products
Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic
Navidea Biopharmaceuticals Regains Compliance with NYSE American Continued Listing Standards
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
IMV Announces Board Retirement
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that Albert Scardino will retire from the IMV Board of
Navidea Biopharmaceuticals Announces $4.2 Million Sale of Ohio Court Judgment and $3.4 Million Equity Raise Representing $7.6 Million in Additional Funding
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Clovis Oncology to Announce Fourth Quarter/Full Year 2019 Financial Results and Host Webcast Conference Call on February 24
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter and full year 2019 financial results on Monday, February 24, 2020, after the close of the U.S. financial markets. Clovis’
Sangamo Therapeutics Appoints John Markels to Its Board of Directors
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Dr. John Markels, an accomplished pharmaceutical executive with three decades of general
4SC: Das könnte für Furore sorgen
4SC (WKN: A14KL7) präsentiert auf dem vom 12.-14. Februar in Barcelona stattfindenden "World Congress of Cutaneous Lymphomas" ein Update zum Fortschritt seiner „Resmain-Studie“ sowie präklinische
Clovis Oncology to Present at the 9th Annual SVB Leerink Healthcare Conference
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the 9th Annual SVB Leerink Global Healthcare Conference on
NANOBIOTIX Announces Fast Track Designation Granted By U.S. FDA For Investigation of First-in-class NBTXR3 In Head and Neck Cancer
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 5, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2019 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, February 20, 2020, following release of its fourth
Aduro Biotech: +142% – Alltag im No Brainer Club
Für die Oktober-Empfehlung des No Brainer Clubs geht es weiter in die Höhe: Aduro Biotech (WKN: A14Q7F) bescherte NBC-Mitgliedern bis heute bereits einen Gewinn von +142%.
Nach dem Erreichen der
Clinical Translational Data Supporting DPX-Survivac Mechanism of Action to be Presented at 2020 ASCO-SITC Clinical Immuno-Oncology Symposium
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that clinical translational data supporting the mechanism
Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in France
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that Rubraca® (rucaparib) is now available and reimbursed in France. Rubraca® (rucaparib) is an option for monotherapy maintenance treatment for
IMV to Present at 2020 BIO CEO & Investor Conference
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that company management will present at the BIO CEO and
Pulmatrix: Wann folgt die Explosion 2.0?
Mit einem Schlusskurs von 1,78 USD markierte die Aktie von Pulmatrix (WKN: A2PD3T) gestern ein neues Langzeithoch. Obwohl NBC-Mitglieder auch hier bereits auf teilweise über +100% Gewinn sitzen
Trevena mit +50% in 7 Wochen - NBC erneut mit Volltreffer-Timing!
Während die Börsen derzeit eine Verschnaufpause einlegen und der für den No Brainer Club besonders relevante NASDAQ Biotechnology Index wieder nahe Jahrestief notiert, kennt unsere Empfehlung des